NCT01725490 - The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study | Biotech Hunter

Enrollment

34

Participants

Timeline

Start Date

February 15, 2013

Primary Completion Date

August 30, 2020

Study Completion Date

August 30, 2020

Conditions

Familial Adenomatous Polyposis

Interventions

DRUG

Metformin

Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.

DRUG

Metformin

Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.

DRUG

Placebo

Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.

Trial Locations (1)

120-752

Department of Internal Medicine, Yonsei University College of Medicine, Seoul